Here's Why Cigna (CI) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 31, 2026

Can Cigna's Smart Coverage Help Close Health-Cost Gaps?

CI's Smart Coverage links medical and supplemental benefits, offering up to $7,000 and automated claims for costly health events.

Zacks Investment Research • Aug 27, 2026

Cigna Healthcare Connects Medical and Supplemental Benefits To Help People Better Manage Unexpected Health Costs

Industry-first connected benefits experience helps people access cash benefits when they need it most and gives employers more affordable coverage options BLOOMFIELD, Conn., Aug. 26, 2026 /PRNewswire/ -- Cigna Healthcare®, the health benefits division of The Cigna Group (NYSE: CI), is introducing a new connected benefits experience that helps people pay for costs associated with unexpected or costly health events by bringing medical and supplemental health benefits together in a simpler, more personalized way.

PRNewsWire • Aug 26, 2026

Zacks Industry Outlook UnitedHealth, The Cigna, Humana, Centene and Molina

UnitedHealth, The Cigna, Humana, Centene and Molina have been highlighted in this Industry Outlook article.

Zacks Investment Research • Aug 25, 2026

Cigna (CI) is a Top-Ranked Growth Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Aug 24, 2026

5 HMO Stocks to Watch Amid Steady Premium Flow, Increased Digitization

An aging U.S. population, digital transformation, a diversified membership mix and strategic M&A are likely to drive the performance of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.

Zacks Investment Research • Aug 24, 2026

Here's Why Investors Should Stay Neutral on Cigna Stock for Now

CI's growth and shareholder returns are weighed against rising costs, medical expenses and debt, keeping investors neutral for now.

Zacks Investment Research • Aug 19, 2026

Cigna: I'm Buying What Others Are Ignoring

Cigna Group remains a "Buy," with double-digit adjusted EPS growth intact and shares trading 28% below fair value. CI's Accredo and AI-powered Pharmacy Forward platforms are key growth drivers, supporting robust revenue and margin expansion through 2028. The company boasts an A- S&P credit rating, strong free cash flow, and a secure, growing dividend with low payout ratios.

Seeking Alpha • Aug 17, 2026

Why Cigna (CI) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Aug 12, 2026

Here's Why Cigna (CI) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 7, 2026